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ABSTRACT 
OLjectives: To assess the efficacy and tolerability of three anti- 
biotic regimens in patients with acute exacerbation of chronic 
bronchitis. 
Methods: In this double-blind, randomized, multicentered, par- 
allel-group study, patients received once-daily cefdinir 600 mg, 
twice-daily cefdinir 300 mg, or twice-daily cefuroxime axetil 
250 mg for IO days. Primary efficacy measures were micro- 
biologic eradication rate, by pathogen and by patient, and clin- 
ical response rate, by patient. 
Results: Of 1045 patients, 589 were evaluable for efficacy. At 
baseline, most patients had moderate or severe cough and 
sputum production as well as rhonchi, wheezing, and dyspnea. 
The microbiologic eradication rates by pathogen were 90% 
with once-daily cefdinir, 85% with twice-daily cefdinir, and 88% 
with twice-daily cefuroxime. The corresponding values for 
microbiologic eradication rate by patient were 90% (once-daily 
cefdinir), 85% (twice-daily cefdinir), and 86% (twice-daily 
cefuroxime). The respective clinical response rates by patient 
were 81%, 74%, and 80%. There were no significant differ- 
ences in the incidence of drug-related adverse events or dis- 
continuations due to adverse events. Diarrhea was the most 
frequent complaint. 
Conc/usions: The results indicate that the efficacy and tolera- 
bility of cefdinir, once or twice daily, and cefuroxime were com- 
parable with no significant differences between the regimens 
used. 
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Chronic bronchitis is a common respiratory disorder 
throughout the world. Defining features can range from 
daily coughs productive of sputum for 3 months per year 
over at least 2 consecutive years to advanced chronic 
obstructive airways disease.’ Factors known to be asso- 
ciated with this disease include cigarette smoking, air pol- 
lution, socioeconomic status, and recurrent childhood 
respiratory infections.z 
Acute exacerbation of chronic bronchitis (AECB) usu- 
ally is associated with common respiratory pathogens, 
such as Haemophilus injikenzae, Streptococcus pneu- 
moniae, and Moraxella catarrhalis, and may be partic- 
ularly severe in the debilitated, in smokers, and in the 
elderly.2-4 
Although most respiratory pathogens are suscepti- 
ble to P-lactam-containing antibiotics, including penicillins 
and cephalosporins, the increasing prevalence of p-lac- 
tamase-producing organisms has increased the rate of 
resistance to established treatments.5Bh The development 
of antibiotics that are stable in the presence of p-lacta- 
mase enzymes is of considerable importance.‘,’ 
Cefdinir is a semisynthetic, extended-spectrum, third- 
generation cephalosporin antibiotic that is intended for 
use in the treatment of mild-to-moderate bacterial 
infections. The drug has good activity against typical res- 
piratory tract pathogens such as H. injluenzae, S.pneu- 
moniae, and M. catarrhaZis.9 Cefdinir also is highly stable 
in the presence of P-lactamase enzymes; and many P-lac- 
tamase-producing bacteria that are resistant to penicillins, 
and some cephalosporins, are susceptible to cefdinir.lOxll 
Cefuroxime is a second-generation cephalosporin with 
proven efficacy against the major pathogens of lower res- 
piratory tract infections (LRTIs).12 It has activity against 
P-lactamase-producing strains of H. influenzae and M. 
catarrhalis, which are resistant to ampicillin or amoxy- 
cillin. Clinical studies have indicated that cefuroxime is 
effective and well tolerated in the treatment of AECB.13 
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The aim of this study was to evaluate the efficacy 
and safety of two dosages of cefdinir (600 mg once daily 
[o.d.] and 300 mg twice daily [b.i.d.]) with cefuroxime 
axetil(25O mg b.i.d.) administered for 10 days in patients 
with AECB. 
MATERIALS AND METHODS 
Patients were enrolled into this double-blind, random- 
ized, parallel-group study from centers in Australia, 
Europe, South Africa, and the United States. Each center 
used a similar protocol that was approved by the local 
Ethics Committee or Institutional Review Board. The trial 
was carried out in accordance with the Declaration of 
Helsinki, and all patients gave written informed consent. 
The first patient was treated in November 1992 and the 
last follow-up visit was in January 1995. 
Patients 
At baseline, each patient’s medical history was taken, and 
he or she underwent a physical examination, chest 
roentgenogram, clinical assessment, Gram stain, sputum 
culture and susceptibility testing, and clinical laboratory 
evaluations (hematology, blood chemistry, and urinalysis). 
Patients were eligible if they were at least 13 years 
old (at least 18 y in Germany and two centers in the 
United Kingdom, and at least 21 y in one center in the 
United Kingdom) and had a history of chronic bronchi- 
tis and a current diagnosis of acute exacerbation of 
chronic bronchitis of presumptive bacterial origin. The 
diagnosis had to be accompanied by cough productive 
of mucopurulent or purulent sputum and a pretreatment 
sputum culture positive for a lower respiratory tract 
pathogen. 
Patients were excluded in the following circum- 
stances: evidence of pneumonia on a pre-screen roent- 
genogram; any disease or condition (e.g., cystic fibrosis, 
bronchiectasis, bronchial carcinoma, or pulmonary struc- 
ture defects) likely to affect evaluation of the study med- 
ication; evidence of significant systemic disease (e.g., 
cardiovascular, gastrointestinal, psychiatric disease); 
hepatic or renal impairment; hypersensitivity to B-lac- 
tams; baseline pathogen known to be resistant to either 
study drug; concomitant infection requiring a systemic 
antibiotic; and use of a systemic antibiotic in the 48 hours 
(or 5 plasma half-lives) prior to starting treatment. 
Patients could enter the study before the results of 
the pretreatment sputum culture and susceptibility tests 
were known. Those with cultures negative for lower res- 
piratory tract pathogens or showing resistant pathogens 
could be withdrawn from the study and treated appro- 
priately if failing, or remain in the study if in the opinion 
of the investigator there was satisfactory clinical improve- 
ment. However, such patients were not considered 
evaluable 
Pathogens 
The genus and species of all pathogens isolated from cul- 
tures were identified. The individual investigators together 
with the microbiologist of the laboratory local to the par- 
ticipating center decided in each individual case which 
of the cultured organisms was the causative pathogen. 
All isolates were tested for susceptibility to cefdinir 
and cefuroxime using disk diffusion in agar to determine 
the zone diameter of complete inhibition of bacterial 
growth; susceptibility testing was performed in accor- 
dance with National Committee for Clinical Laboratory 
Standards or appropriate local guidelines.l*-I6 Isolated 
pathogens also were subjected to serial dilution mini- 
mum inhibitory concentration (MIC) determination for 
cefdinir, using Sensititre@ (Accumed Inc., Westlake, Ohio) 
microbroth MIC plates containing 12 serial dilutions of 
cefdinir (range, 0.015-32 mg/L). 
The isolated pathogens were tested, if appropriate, for 
B-lactamase production, using the cefinase disk for H. 
infuenzae, M. catarrhalis, and S. aureus. 
Treatment Randomization and Blinding 
Each patient was randomized to receive cefdinir 600 mg 
once a day, 300 mg twice a day, or cefuroxime axetil 
250 mg twice a day, for 10 days, the latter being used as 
an active control in preference to a placebo. 
An independent, computer-generated randomization 
schedule was prepared for each study center. A block 
size of six patients was used, with three treatment repli- 
cates per block, consistent with the proposed 1: 1: 1 treat- 
ment group ratio. 
Study medication was provided as identical cefdinir, 
cefuroxime, or placebo capsules, packaged for each cen- 
ter and pre-labelled with sequential patient numbers, 
according to the randomization schedule. At each study 
center, patients who met the entry criteria at screening 
were given the next consecutive patient number and dis- 
pensed the corresponding pre-labelled study medication. 
Measurement of Efficacy 
Efficacy was assessed at a test-of-cure (TOC) visit between 
7 and 14 days post-treatment and a long-term follow-up 
(LTFU) visit between 21 and 35 days post-treatment. The 
LTFU assessment provided information on recurrence of 
infection. The primary measures of efficacy included 
microbiologic eradication rate by pathogen and clinical 
response rate. 
Microbiologic responses by pathogen at the TOC and 
LTFU visits were categorized as “eradication” (no baseline 
pathogen in the follow-up culture or no sputum avail- 
able for culture, owing to presumed eradication), “per- 
sistence” (baseline pathogen present in follow-up culture), 
or “not assessable.” 
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Clinical assessment of patients included the investi- 
gators’ evaluations of signs and symptoms, such as cough; 
sputum production and appearance; dyspnea; rales; 
rhonchi; fremitus; wheezing; pleural rub; and fever. The 
clinical response at the TOC visit was categorized as 
“cure” (absence or satisfactory remission of all baseline 
signs and symptoms), “failure” (no significant remission of 
baseline signs and symptoms), or “not assessable.” No 
outcome of “improved” was used. At the LTFU visit, the 
failure category was replaced by “failure/recurrence” 
(worsening or no significant remission of baseline signs 
and symptoms since the previous visit). 
A secondary efficacy parameter was the appearance 
of new pathogens during or after treatment. These were 
categorized as “superinfection” (appearance of a non-base- 
line pathogen up to and including the TOC visit and less 
than 50% clinical improvement, based on a standardized 
clinical algorithm), “reinfection” (appearance of a new 
pathogen and classification of recurrence at LTFU) or “not 
assessable.” 
The populations that were evaluated for efficacy 
included the evaluable patient group (those with a base- 
line pathogen and no major protocol violations likely to 
affect assessment of efficacy), the intent-to-treat (ITT) 
group (patients who were randomized to treatment), and 
at the LTFU visit, the group of qualified patients (evalu- 
able patients who did not have additional protocol vio- 
lations between TOC and LTFU). 
Measurement of Tolerability 
Each patient who was randomized to treatment and who 
received study medication was evaluated for safety Eval- 
uations of cefdinir and cefuroxime were based on the 
frequency of adverse events, their intensity, the frequency 
of treatment discontinuation due to adverse events, and 
the outcome of physical examinations and clinical labo- 
ratory tests. 
Adverse events included any concurrent illness or 
symptom (except those related to chronic bronchitis) 
reported by the investigators during the study; these com- 
plaints were converted to the preferred coding symbols 
for thesaurus of adverse reaction terms (COSTAKI’).‘7 
Statistics 
The study was designed with a sample size of 190 evalu- 
able patients per randomized group (n = 3) (1140 
patients, if the evaluability rate is 50%). A microbiologic 
eradication rate of 90% was assumed in the sample-size 
calculation. The sample size was calculated to provide at 
least 80% power to assess the equivalence of the cefdinir 
and cefuroxime microbiologic eradication rates at the 
TOC visit. 
In relation to efficacy, two-tailed 95% confidence 
intervals (CD about the difference between response rates 
(e.g., cefdinir o.d. minus cefuroxime b.i.d.) were calcu- 
lated, using pooled estimates of treatment group response 
rates, and compared with a set of fixed criteria. For any 
two regimens to be equivalent, each 95% confidence 
interval had to contain 0 and fall within specific bound- 
aries (if the estimated response rate [ERR] was 290%, the 
95% CI for the difference had to be i-10%; if the ERR 
was SO-S9%, the 95% CI had to be 2 15%; and if the ERR 
was 70-79%, the 95% CI had to be t-20%). 
An exploratory Co&ran-Mantel-Haenszel (CMH) test 
was used to compare differences between treatment 
groups. The Breslow-Day test was employed to evaluate 
treatment-by-center interaction. 
A CMH test, adjusting for center, was performed to 
compare differences between treatment groups (pair- 
wise) in terms of the rates of drug-related adverse events, 
diarrhea, and treatment discontinuations due to adverse 
events. 
RESULTS 
Patients (n = 1045) in 36 centers were randomized to 
treatment with cefdinir once a day (n = 349) cefdinir twice 
a day (n = 347) or ceftu-oxime twice a day (n = 349). 
Patients were equally distributed among the treatment 
groups in terms of age, sex, and prior medical history; how- 
ever, there were more males than females within each treat- 
ment group (Table 1). Most patients were in the age range 
18 to 64 years (63%) and approximately one-third (36%) 
of all patients was aged 65 or over (not shown). 
Table 1. Patient Characteristics and Baseline Symptoms 
Intent-to-Treat Group Evaluable Test-of-Cure 
(n = 1045) Group (n = 589) 
Cefdinir Cefdinir Cefuroxime Cefdinir Cefdinir Cefuroxime 
Once a Day Twice a Day Twice a Day Once a Day Twice a Day Twice a Day 
Number of patients 349 347 349 201 195 193 
Male : female (%)* 64136 58:42 60:40 62:38 61:39 57142 
Median age (y) 
(raw Y) (185-91, (1::s) (2cY92) (1 s5:9, (215-988) (2cE36, 
Medical history (%) 
21 episode of LRTI within last 12 months 63 70 72 - 
*Percentages are rounded and may not add up to 100%. LRTI = lower respiratory tract infection. 
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Over 95% of enrolled patients had a moderate or 
severe cough at baseline, and over 90% had moderate or 
severe sputum production. Most patients also had rhonchi 
(71%) and wheezing (52%) and almost half had moder- 
ate or severe dyspnea (49%). Approximately one-third of 
patients presented with rales, 20% with fever, and less 
than 10% with fremitus or pleural rub. Similar numbers 
of patients had experienced lower respiratory tract infec- 
tions (LRTIs) in the year preceding the study (see Table 
1). In each treatment group, 34% of patients were past 
smokers and between 28% and 32% were current 
smokers. 
In 752 of 1045 patients (72%) 882 pathogens were 
isolated at baseline and multiple pathogens were cultured 
from 115 patients (11%). The most common pathogens 
were H. influenzae, S.pneumoniae, H. parainfluenzae, 
and S. aureus. Over 94% of pathogens tested were sus- 
ceptible to both study drugs (Table 2). The number of 
pathogens resistant to cefdinir and cefuroxime was 36 of 
867 (4%) and 28 of 863 (3%) respectively (see Table 2). 
Thirty-one isolates of Spneumoniae were tested for 
penicillin susceptibility at baseline, all were susceptible 
to penicillin. All but one of these isolates were tested for 
cefdinir and cefuroxime susceptibility and all 30 were 
found to be susceptible to both drugs. 
Among all patients treated, 940 (90%) completed a 
median of 10 days of treatment with study medication, 
with no differences among the three regimens. At the 
TOC visit, 456 patients were unevaluable mainly owing 
to absence of a baseline pathogen. Thus, 589 patients 
were included in the evaluable patient population. A 
further 173 patients were disqualified from the analyses 
at the LTFU visit, mainly owing to missing cultures or no 
clinical assessment, leaving 
group. 
Efficacy 
Test-of-Cure Assessment 
416 patients in the qualified 
In the evaluable group, the microbiologic eradication 
rates by pathogen were 90% in the cefdinir once a day 
group, 85% in the cefdinir twice a day group, and 88% in 
the cefuroxime twice a day group (Table 3; Figure 1). 
The 95% confidence interval for the comparison of erad- 
ication rates by pathogen indicated that cefdinir once a 
day and cefdinir twice a day were comparable to cefurox- 
ime twice a day, but that cefdinir once a day was slightly 
more effective than cefdinir twice a day (see Figure 1). 
The clinical response rates with cefdinir once a day, 
cefdinir twice a day, and cefuroxime twice a day were 
81%, 74%, and 80%, respectively (see Figure 1). The 95% 
confidence interval for the comparisons of clinical 
response showed that there were no differences among 
the three regimens. 
The exploratory CMH tests showed no significant 
differences between the drugs on any efficacy parameter 
at the TOC visit. 
Clinical cure rates in patients 65 years of age and 
older were similar to those in younger adults in all treat- 
ment groups (Table 4). Smoking history did not appear 
to affect successful clinical outcomes, except among 
Pathogen (n = 882) 
Table 2. Pathogen Susceptibility to Treatment at Baseline 
Cefdinir 
(n =S7g8) (n =R3fJ (n =?752) 
Cefuroxime 
(n 183) (n =R28) 
Gram-positive 
Streptococcus pneumoniae (n = 137) 132 0 4 1 132 2 1 2 
Staphylococcus aureus (n = 74) 69 0 3 2 68 2 1 3 
Streptococcus pyogenes (n = 17) 17 0 0 0 15 2 0 0 
Other (n = 8) 8 0 0 0 6 2 0 0 
Gram-negative 
Haemophilus influenzae 
p-lactamase + (n = 29) 29 0 0 0 28 1 0 0 
p-lactamase - (n = 243) 218 19 3 3 233 3 4 3 
p-lactamase unknown (n = 5) 5 0 0 0 5 0 0 0 
Haemophilus parainfluenzae 
P-lactamase + (n = 10) 8 1 1 0 10 0 0 0 
p-lactamase - (n = 63) 56 4 1 2 61 2 0 0 
p-lactamase unknown (n = 12) 10 0 2 0 12 0 0 0 
Moraxella catarrhalis 
p-lactamase + (n = 37) 37 0 0 0 34 3 0 0 
p-lactamase - (n = 37) 35 2 0 0 33 3 0 1 
p-lactamase unknown (n = 2) 0 0 0 2 0 0 0 2 
Escherichia co/i (n = 52) 49 0 2 1 32 18 0 2 
Klebsiella pneumoniae (n = 30) 30 0 0 0 22 8 0 0 
Other (n = 126) 95 7 20 4 61 37 22 6 
S = susceptible (ME < 0.06 mg/L); I = intermediate susceptibility (MIC 0.1-l .O mg/L); R = resistance (MIC > 2.0 mg/L); U = unknown; + = positive; - = negative. 
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Table 3. Microbiologic Eradication Rate by Pathogen at Test-of-Cure and Long-Term Follow-up Examinations 
Number of Pathogens 
Pathogen 
Gram-positive 
S. aureus 
S. pneumoniae 
S. pyogenes 
Other 
At Test-of-Cure Visit (n = 666) At Long-Term Follow-up Visit (n = 430) 
Cefdinir o. d. Cefdinir b. i. d. Cefuroxime b. i. d. Cefdinir o. d. Cefdinir b. i. d. Cefuroxime b.i.d. 
199/221 192/225 193/220 144/152 134/136 140/142 
(98.0%) (85.3%) (87.7%) (94.7%) (98.5%) (98.6%) 
16/16 19/20 23/23 10/10 10/11 18/18 
34/38 35/40 30/30 23/27 27/27 21/21 
4/4 4/5 4/4 3/3 3/3 l/i 
o/o 3/3 2/2 o/o o/o 2/2 
Gram-negative 
t-l. influenzae 
p-lactamase + 
P-lactamase - 
P-lactamase unknown 
l-l. parainfluenzae 
p-lactamase + 
p-lactamase - 
p-lactamase unknown 
M. catarrhalis 
p-lactamase + 
p-lactamase - 
p-lactamase unknown 
E. co/i 
K pneumoniae 
Other 
4/4 4/7 
51165 53/66 
l/i i/i 
2/2 
13/13 
4/4 
14/14 
5/5 
IO/12 
12/12 
29131 
3/3 
21/24 
3/3 
4/6 
13/14 
7/9 
6/B 
16/16 
B/10 - - - 
43160 - - - 
l/i 38/42* 40/40* 38/39* 
3/3 - 
15/16 
2/2 13/13* 19/19* 13/l 3* 
B/9 - - - 
12/12 - - 
15/l 5* 11/11* 14/l 4* 
13116 8/B 5/6 13/13 
313 8/B 313 3/3 
26129 26126 16/16 17118 
+ = positive; - = negative. *Combined p-lactamase categories. 
cefuroxime-treated patients, in whom clinical cure rates 
were slightly higher among patients who had never 
smoked. 
In the ITT population, analyses of the 95% confidence 
interval for microbiologic eradication rates by pathogen 
and by patient, and the clinical response by patient, con- 
firmed that cefdinir once a day, cefdinir twice a day, and 
cefuroxime twice a day had comparable efficacy. 
Long-Term Follow-up Assessment 
At LTFU assessment, the three regimens were compara- 
ble as judged by the three primary measures of efficacy 
(see Table 3 and Figure 1). The microbiologic eradication 
rates by pathogen were 95% with cefdinir once a day, 
99% with cefdinir twice a day, and 99% with cefuroxime 
twice a day. The corresponding values for clinical 
response by patient were 93%, 95%, and 93%, respectively 
(see Figure 1). 
The analysis of data from the ITT population at the 
LTFU visit showed that all three treatment groups had 
comparable responses. 
During the study, 116 patients developed a respira- 
tory tract superinfection: 32 patients in the cefdinir once 
a day group, 45 in the cefdinir twice a day group, and 39 
in the cefuroxime twice a day group. Eleven patients 
were reinfected after the TOC visit with pathogens not 
present at baseline: three patients in the cefdinir once a 
day group, six patients in the cefdinir twice a day group, 
and two in the cefuroxime twice a day group. 
Tolerability 
Two patients who were randomized to treatment did not 
receive study medication. Thus, 1043 were evaluated for 
safety: 349 receiving cefdinir once a day, 345 receiving cef- 
dinir twice a day, and 349 receiving cefuroxime twice a 
day (see Table 4). 
Overall, adverse event rates during therapy were sim- 
ilar in each group. Drug-related adverse events were 
observed in 50 of 349 patients (14%) with cefdinir once 
a day, 44 of 345 (13%) with cefdinir twice a day, and 39 
of 349 (11%) with cefuroxime twice a day. There were 
no statistically significant differences among the regimens. 
Most adverse events occurred within the first 5 days of 
treatment and were mild or moderate in intensity 
The majority of complaints related to the digestive 
system. Diarrhea was the most frequent drug-related 
adverse event, occurring in 29 patients (8.3%) receiving 
cefdinir once a day, 27 (7.8%) receiving cefdinir twice a 
day, and 19 (5.4%) receiving cefuroxime twice a day, fol- 
lowed by nausea in seven (2%) three (0.9%) and eight 
patients (2.3%), respectively. Other adverse events 
occurred with a frequency of less than 2%. 
Severe gastrointestinal hemorrhage occurred in one 
patient after 4 days of treatment with cefuroxime twice 
a day This was the only serious adverse event that was 
considered possibly related to treatment. Thirty-four 
patients discontinued treatment because of adverse 
events that were considered related to treatment (15 in 
the cefdinir o.d. group, 10 in the cefdinir b.i.d. group, 
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Erad (TOC) 
Erad (LTFU) 
Clin. cure (TOC) 
Clin. cure (LTFU) 
95% Cl Fixed Criteria (%) Result 
Microbiologic eradication rate by pathogen 
Cefdinir od-cefuroxime b.i.d 
Cefdinir b.i.d.-cefuroxime b.i.d. 
Cefdinir o.d.-cefdinir b.i.d. 
Clinical response rate 
Cefdinir od-cefuroxime b.i.d 
Cefdinir b.i.d.+efuroxime b.i.d. 
Cefdinir o.d.-cefdinir b.i.d. 
Analyses based on pooled rates at the test-of-cure visit. 
-3.5, 8.2 t 10 
-8.7, 3.9 L 15 
-1.4, 10.8 2 10 
-7.0, 8.6 2 15 
-14.3, 2.4 + 15 
-1.4, 14.9 -c 15 
Equivalent 
Equivalent 
Not equivalent 
Equivalent 
Equivalent 
Equivalent 
Figure 1. Graphic illustration of overall treatment response (top); table presenting 95% confidence interval for comparison of eradication rates and 
clinical response rates (analyses based on pooled rates at test-of-cure) (bottom). Erad = eradication rate; TOC = test-of-cure; LTFU = long-term 
follow-up; clin. cure = clinical response. 
and 9 in the cefuroxime b.i.d. group), the most frequent 
reason being diarrhea. Pairwise comparisons showed no 
differences in discontinuation rates among the treatment 
groups. Rash caused discontinuation in 1% of each cef- 
dinir group and in 0% of the cefuroxime-treated patients. 
No clinically important adverse events were noted dur- 
ing physical examinations or clinical laboratory tests. 
DISCUSSION 
This was a large, multicenter, double-blind study designed 
to evaluate the efficacy and safety of two dosages of 
Table 4. Clinical Cure Rates at Test-of-Cure by Patient 
Age and Smoking History among Evaluable Patients 
Cefdinir o.d. 
n (%) 
Patient age (y) 
18-64 100/l 29 (77.5) 
265 63/72 (87.5) 
Smoking history 
Current smoker 48/60 (80.0) 
Past smoker 56/70 (80.0) 
Never smoked 59/71 (83.1) 
Cefdinir b.i. d. Cefuroxime b.i.d. 
n (%) n (%) 
98/134 (73.1) 102/122 (83.6) 
47161 (77.0) 53/71 (74.6) 
42160 (70.0) 50/60 (83.3) 
55/72 (76.4) 46/69 (66.7) 
48/63 (76.2) 59/64 (92.2) 
cefdinir versus cefuroxime in the treatment of patients 
with AECB. The study group comprised 1045 patients 
who were randomized to receive either cefdinir or 
cefuroxime. The results indicate that the efficacy and tol- 
erability of cefdinir and cefuroxime were comparable 
with no significant differences among the regimens used. 
In the test population, patients had to have AECB of 
presumptive bacterial origin. Nonbacterial respiratory 
pathogens (e.g., mycoplasma, chlamydia, legionella, 
influenza, and other viral causes) were not assessed. It 
was found that the bacterial pathogens responsible for 
ABCB in this study were typical of those associated with 
AECB, and they responded well to cefdinir and cefurox- 
ime. Nevertheless, the exact role of bacterial and viral 
infection in AECB has been disputed; bacterial coloniza- 
tion has been found during remission periods as well as 
during acute exacerbations. l8 There is a lack of clear data 
identifying patients who might benefit from antibiotic 
treatment, although some believe that antibiotics should 
be reserved for those with pneumonia.18 
In this study, AECB responded comparably to the 
two antibiotics. At the TOC assessment, the 95% confi- 
dence interval for the comparison of eradication rates by 
pathogen and the clinical response rate by patient indi- 
cated that cefdinir once a day and twice a day were 
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Table 5. Summary of Drug-Related Adverse Events 
Number of patients 
Cefdinir o. d. Cefdinir b.i. d. 
349 345 
Cefuroxime b.i.d. 
349 
Drug-related adverse events by body system (n) 50 44 39 
Digestive system 37 36 31 
Diarrhea 29 27 19 
Nausea 7 3 8 
Skin and appendages 9 6 1 
Body as a whole 7 4 7 
Urogenital system 3 1 1 
Special senses 1 1 2 
Nervous system 1 0 1 
Metabolic or nutritional 0 1 0 
Blood and lymphatic systems 0 0 0 
Musculoskeletal 0 0 0 
Cardiovascular system 0 0 0 
Respiratory system 0 0 0 
Intensity of drug-related events (%) 
Mild 8.9 7.2 8.0 
Moderate 6.0 5.2 2.3 
Severe 1.1 0.3 1.1 
Treatment discontinuation owing to drug-related adverse events n (%) 15 (4.3) IO (2.9) 9 (2.6) 
*Percentage of patients with multiple adverse events counted once in each applicable category. A patient could have more than one adverse event per body system. 
equivalent to cefuroxime twice a day Overall, the clini- 
cal response rates were somewhat lower than the micro- 
biologic response rates (7481% vs. SS-90%) which may 
be attributable to underlying viral infections that also 
can cause AECB.Z Furthermore, the responses to cefdinir 
twice a day were slightly lower than those with cefdinir 
once a day and cefuroxime twice a day (74-85% vs. 
SO-90%). However, an exploratory CMH test showed no 
significant differences among the regimens on any effi- 
cacy parameter at this visit. 
Similar relapse rates were seen in patients receiving 
cefdinir and cefuroxime. At the LTFU assessment, all three 
drug regimens were comparable in patients who had 
eradication at the TOC visit, as judged by the primary 
efficacy measures. These findings indicated that cefdinir 
and cefuroxime continued to provide good response in 
those patients in whom treatment initially was successful. 
In a randomized, double-blind, crossover comparison 
of broad-spectrum antibiotic and placebo therapy in 173 
patients with exacerbation of chronic obstructive 
pulmonary disease (COPD), the success rate was 55% 
with placebo and 68% with either trimethoprim- 
sulphamethoxazole, amoxicillin, or doxycycline.19 The dif- 
ference between antibiotic and placebo was greatest in 
patients with type 1 exacerbation (the occurrence of 
increased dyspnea, sputum volume, and sputum puru- 
lence).r9 The present study did not stratify patients by 
exacerbation type, because pre-exacerbation rates were 
not available; in addition, the sample sizes became too 
small for effective analysis and statistical testing. However, 
most of the patients in the study could be categorized as 
those having type 1 exacerbation, in whom, according to 
the work of Anthonisen et al,19 one would expect a “large 
advantage for antibiotic therapy.” In support of antibiotic 
use in AECB, a meta-analysis of randomized trials has indi- 
cated that there was a small but statistically significant 
improvement attributable to antibiotic therapy in patients 
with exacerbation of COPD that may be clinically signif- 
icant in those with low baseline flow rates.*O 
Although there were no patients with known peni- 
cillin-resistant isolates of S. pneumoniae, three cefdinir- 
treated patients were noted to have cefdinir-resistant 
strains of Spneumoniae. In each case, the category of 
clinical response at TOC was cure; one patient had micro- 
biologic persistence at TOC, whereas the other two had 
eradication. The investigators also identified 20 H; ivzfuen- 
zae isolates that were B-lactamase-negative and amoxi- 
cillin-resistant. At the short-term follow-up, the clinical 
and microbiologic responses of 12 of these isolates were 
categorized as cure and eradication, and with four iso- 
lates the responses were categorized as cure and persis- 
tence, respectively. These findings suggest that cefdinir is 
effective against pathogens that are resistant to standard 
agents. 
Although this study did not specifically consider 
causative factors associated with AECB, it may be rele- 
vant that approximately one-third of patients were past 
smokers, about the same proportion were currently smok- 
ing, and one-third were elderly (over 65 years). In the 
cohort investigated by Anthonisen and colleagues,19 94% 
of the patients had a history of smoking, with 21% still 
smoking at the time of enrollment; the average age of 
their patients was 67 years. 
Cefdinir and cefuroxime were equally well tolerated 
with no significant differences among regimens. Most 
adverse events occurred in the first 5 days of treatment 
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and were mild or moderate in intensity. Diarrhea was the 
most frequent drug-related complaint with both drugs. 
There were no significant differences between cefdinir 
and cefuroxime in terms of discontinuations owing to 
adverse events. Indeed, the safety profile of cefdinir was 
similar to that of cefuroxime and other cephalosporins 
used for LRTIs, including AECB.3,4,21-23 
CONCLUSIONS 
Cefdinir 600 mg once a day was as effective as cefurox- 
ime 250 mg twice a day in terms of microbiologic 
response by pathogen and clinical response in patients 
with AECB of presumptive bacterial origin. Cefdinir 300 
mg twice a day was as effective as cefuroxime twice a day 
in terms of microbiologic response by patient. All three 
treatments were well tolerated with no significant dif- 
ferences among regimens in terms of frequency of 
adverse events or numbers of patients discontinuing treat- 
ment because of adverse events. 
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